Capecitabine plus paclitaxel induction treatment in gastric cancer patients with liver metastasis: a prospective, uncontrolled, open-label Phase II clinical study.

Abstract

AIM:

To determine the overall survival rate, radical resection rate, objective response rate and safety of capecitabine plus paclitaxel induction chemotherapy in gastric cancer patients with liver metastases.

PATIENTS & METHODS:

A total of 30 patients (median age: 59.5 years) diagnosed as gastric adenocarcinoma with liver metastasis received ≥3 cycles of capecitabine and paclitaxel therapy followed by radical resection 4-6 weeks after termination of chemotherapy.

RESULTS:

The median survival time was 11.4 months, and the objective response rate was 53.3%. The radical resection rate was 23.3% (95% CI: 9.9-42.3). Major toxicities included grade 3 neutropenia (10.0%) and grade 3 diarrhea (3.3%).

CONCLUSION:

Capecitabine plus paclitaxel chemotherapy may be effective and safe to improve overall survival and the resection rate of gastric cancer patients with liver metastases. ClinicalTrials.gov identifier: NCT0116704.

• Authors: Ai-Wen Wu, Peng Yuan, Zi-Yu Li, Lei Tang, Zhao-De Bu, Hui Ren, Jia-Fu Ji
• Journal: Future oncology (London, England) (Future Oncol) Vol. 12 Issue 18 Pg. 2107-16 (Sep 2016) ISSN: 1744-8301 [Electronic] England
• PMID: 27256000 (Publication Type: Clinical Trial, Phase II, Journal Article)

Chemical References

• Capecitabine
• Paclitaxel

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Capecitabine
• Combined Modality Therapy
• Disease Progression
• Female
• Humans
• Induction Chemotherapy
• Liver Neoplasms (drug therapy, mortality, secondary)
• Male
• Middle Aged
• Neoplasm Staging
• Paclitaxel (administration & dosage)
• Retreatment
• Stomach Neoplasms (drug therapy, mortality, pathology)
• Survival Analysis
• Treatment Outcome